Health Condition 1: null- Metabolic syndrome
Conditions
Interventions
Intervention1: Liposomal Vitamin C: Dose: 5 ml contains 1000 mg of Vitamin C, Route: Oral administration, Frequency: 4 times X 5 ml per day
Control Intervention1: Non Liposomal Vitamin C: Dose: 5 ml c
Sponsors
CureSupport
Eligibility
Inclusion criteria
Inclusion criteria: 1. 18 years of age and above 2. Metabolic abnormalities with or without alcohol consumption and/or smoking 3. Diagnosis of MetS ie. the presence of three or more criteria of the modified National Cholesterol Education Programs Adult Treatment Panel III ( NCEP ATP III: 3.1 Waist circumference 90 cm in men and 80 cm in women 3.2 Hypertriglyceridemia >= 150 mg/dl 3.3 High density lipoprotein (HDL) cholesterol 40 mg/dl in males and 50 mg/dl in females 3.4 Blood pressure >= 130/85 mm Hg 3.5 Fasting plasma glucose >= 110 mg/dl 3.6 Patients willing to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Acute illness within the past 2 weeks 2. Pregnancy or breastfeeding 3. Lack of compliance with the study medication (defined as not using the medication for >1 week) 4. Documented intolerability to vitamin C 5. Participation in a concomitant trial 6. Hypersensitivity to the study medication 7. Regularly used nonsteroidal anti-inflammatory drugs (naproxen and cyclooxygenase-2 inhibitors) and/or cholesterol-lowering agents (statins) 8. Suffered from systemic and inflammatory diseases that change physical or laboratory tests (arthritis, renal, thyroid, hepatic, respiratory, gout, active malignant disease) 9. Impossibility to give informed consent 10. Intake of drugs or dietary supplements 11. Previous illnesses such as heart attack, cancer or dementia 12. Addiction illness
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose, Body weight, anthropometric assessments, Systolic blood pressure, Diastolic blood pressure, Hematology and Biochemistry Quality of life using SF-36 questionnaireTimepoint: Baseline and at 8 weeks | — |
Primary
| Measure | Time frame |
|---|---|
| Immune markers assessment: IgA, IgG and IgM Inflammatory marker C-reactive protein (CRP)Timepoint: Baseline and Week 8 | — |
Countries
India
Contacts
Public ContactDivya Chandradhar
Bio Agile Therapeutics Pvt. Ltd.
Outcome results
None listed